119 related articles for article (PubMed ID: 12034044)
1. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study.
Tassopoulos NC; Vafiadis I; Tsantoulas D; Syrokosta J; Hatzis G; Delladetsima JK; Demonakou M; Sypsa V; Hatzakis AE
J Interferon Cytokine Res; 2002 Mar; 22(3):365-9. PubMed ID: 12034044
[TBL] [Abstract][Full Text] [Related]
2. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
3. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
[TBL] [Abstract][Full Text] [Related]
4. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
[TBL] [Abstract][Full Text] [Related]
5. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.
McHutchison JG; Shad JA; Gordon SC; Morgan TR; Ling MH; Garaud JJ; Albrecht JK; Dienstag JL
J Viral Hepat; 2001 Nov; 8(6):414-20. PubMed ID: 11703572
[TBL] [Abstract][Full Text] [Related]
6. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
[TBL] [Abstract][Full Text] [Related]
8. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
Inoue K; Sekiyama K; Yamada M; Watanabe T; Yasuda H; Yoshiba M
J Gastroenterol; 2003; 38(6):567-72. PubMed ID: 12825133
[TBL] [Abstract][Full Text] [Related]
9. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
10. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.
Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):213-9. PubMed ID: 15908318
[TBL] [Abstract][Full Text] [Related]
12. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy.
Tsuda N; Yuki N; Mochizuki K; Nagaoka T; Yamashiro M; Omura M; Hikiji K; Kato M
J Med Virol; 2004 Nov; 74(3):406-13. PubMed ID: 15368524
[TBL] [Abstract][Full Text] [Related]
14. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study.
Sangiovanni A; Morales R; Spinzi G; Rumi M; Casiraghi A; Ceriani R; Colombo E; Fossati M; Prada A; Tavani E; Minoli G
Hepatology; 1998 Mar; 27(3):853-6. PubMed ID: 9500717
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy.
Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
Intervirology; 2014; 57(5):289-96. PubMed ID: 24992890
[TBL] [Abstract][Full Text] [Related]
16. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values.
Lee SS; Sherman M
J Viral Hepat; 2001 May; 8(3):202-5. PubMed ID: 11380798
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.
Kakizaki S; Takagi H; Yamada T; Ichikawa T; Abe T; Sohara N; Kosone T; Kaneko M; Takezawa J; Takayama H; Nagamine T; Mori M
J Viral Hepat; 1999 Jul; 6(4):315-9. PubMed ID: 10607246
[TBL] [Abstract][Full Text] [Related]
19. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
[TBL] [Abstract][Full Text] [Related]
20. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]